Do serial natriuretic peptide measurements improve prediction of imminent cardiovascular death or heart failure hospitalization in patients with coronary artery disease and type 2 diabetes?
Serial natriuretic peptide measurements improve the short-term risk prediction of cardiovascular death or heart failure hospitalization in patients with CAD and type 2 diabetes.
<0.0001), with a majority of moderate-risk patients (6-month risk between 1% and 10%) being reclassified on the basis of the second NP sample. Conclusions Serial NP measurements improved prediction of imminent cardiovascular death or HFH in patients with coronary artery disease and type 2 diabetes. The absolute risk estimates provided may aid clinicians in decision-making and help patients understand their short-term risk profile.
Wolsk et al. (Wed,) studied this question.